Previous Close | 0.1300 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 3.00 |
Expire Date | 2025-01-17 |
Day's Range | 0.0700 - 0.1300 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, in Baltimore, MD. Ginkgo will present three posters in cell therapy and give one oral presentation in mRNA therapeutics. These presentations demonstrate the power of Ginkgo's platform to drive innovation in the discovery and development of genetic medicines.
Key Insights Significantly high institutional ownership implies Ginkgo Bioworks Holdings' stock price is sensitive to...
Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2024, on Thursday, May 9, 2024, beginning at 5:30 p.m. ET.